Edgewise Therapeutics appoints Arlene Morris to Board of Directors, effective May 6, 2024

Edgewise Therapeutics, Inc.

Morris replaces Peter Thompson on the Audit and Compensation Committees.
She brings 30+ years of biotech leadership, including CEO roles at Syndax and Affymax.
Annual cash retainer of $40,000 plus $7,500 for Audit and $5,000 for Compensation Committee service.
New director stock option grant with ~$500,000 fair value, vesting monthly over 3 years.
Appointment fills vacancy left by Kenneth Harrison's resignation in June 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Arlene Morris

Director

EWTX · Edgewise Therapeutics, Inc.

Effective: 2024-05-06
Filed: May 7, 2024, 7:59 PM ET

On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Arlene Morris was appointed as Director at Edgewise Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.

View on SEC.gov

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-057783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.